Tourmaline Bio to Present at Upcoming Investor Conferences
2024年9月3日 - 8:45PM
Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage
clinical biotechnology company developing transformative medicines
to dramatically improve the lives of patients with life-altering
immune and inflammatory diseases, today announced that Sandeep
Kulkarni, CEO, is expected to participate in the following investor
conferences:
H.C. Wainwright 26th
Annual Global Investor Conference, New
YorkFireside ChatMonday, September 9,
2024 at 12:00 pm ET
Cantor Global Healthcare Conference, New
YorkFireside ChatTuesday, September 17,
2024 at 3:40 pm ET
A live webcast of both presentations will be
available under "Events and Presentations" in the News &
Investors section of the Tourmaline Bio website at
ir.tourmalinebio.com. A replay of the webcasts will be archived on
the Tourmaline Bio website following each event.
About Tourmaline
BioTourmaline is a late-stage clinical biotechnology
company driven by its mission to develop transformative medicines
that dramatically improve the lives of patients with life-altering
immune and inflammatory diseases. Tourmaline’s lead asset is
pacibekitug (also referred to as TOUR006).
About PacibekitugPacibekitug
(also referred to as TOUR006) is a long-acting, fully-human,
anti-IL-6 monoclonal antibody with best-in-class potential and
differentiated properties including a naturally long half-life, low
immunogenicity, and high binding affinity to IL-6. Pacibekitug has
been previously studied in 448 participants, including patients
with autoimmune disorders, across six completed clinical trials.
Tourmaline is developing pacibekitug in TED and ASCVD as its first
two indications, with additional diseases under consideration.
Investor ContactMeru AdvisorsLee M.
Sternlstern@meruadvisors.com
Media ContactScient PRSarah
MishekSMishek@ScientPR.com
Tourmaline Bio (NASDAQ:TRML)
過去 株価チャート
から 9 2024 まで 10 2024
Tourmaline Bio (NASDAQ:TRML)
過去 株価チャート
から 10 2023 まで 10 2024